High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer

Journal of Urology

Volumn 166, Issue 3, 2001, Pages 876-881

  Zelefsky, Michael J ^a   Fuks, Zvi ^b   Hunt, Margie ^b   Lee, Henry J ^b   Lombardi, Danna ^b   Ling, Clifton C ^b   Reuter, Victor E ^b   Venkatraman, E S ^b   Leibel, Steven A ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Memorial Sloan Kettering Cancer Center ^*

Author keywords

Prostate; Prostatic neoplasms; Radiation dosage; Radiotherapy, conformal; Risk

Indexed keywords

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; COMPUTER ASSISTED RADIOTHERAPY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RADIATION DOSE; RADIATION HAZARD; RISK BENEFIT ANALYSIS; SURVIVAL RATE; TOXICITY; TREATMENT OUTCOME;

EID: 0034891284     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)65855-7     Document Type: Article

References (38)

1. Radiation therapy for clinically localized prostate cancer: A multi-institutional pooled analysis
2. The prognostic significance of post-irradiation biopsy results in patients with prostatic cancer
3. Extended biopsy followup after full course radiation for resectable prostatic carcinoma
4. Routine prostate biopsies following radiotherapy for prostate cancer: Results for 226 patients
5. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer
6. The effect of dose on local control of prostate cancer
7. External beam radiotherapy dose-response of prostate cancer
8. Late radiation damage in prostate cancer patients treated by high dose external radiotherapy in relation to rectal dose
9. The biological basis and clinical application of three-dimensional conformal external beam radiation therapy in carcinoma of the prostate
10. Three-dimensional conformal radiotherapy and dose escalation: Where do we stand?
11. The feasibility of dose escalation with three-dimensional conformal radiotherapy in patients with prostatic carcinoma
12. Long term tolerance of high dose three dimensional conformal radiotherapy in patients with localized prostate cancer
13. Three-dimensional conformal radiation therapy in localized carcinoma of the prostate: Interim report of a phase I dose-escalation study
14. Dose escalation with three dimensional conformal radiation therapy affects the outcome in prostate cancer
15. Locally advanced prostatic cancer: Long-term toxicity after three-dimensional conformal radiation therapy-a dose-escalation study
16. Prostate
17. Histologic grading and clinical staging of prostatic carcinoma
18. Conformal radiation treatment of prostate cancer using inversely planned intensity-modulated photon beams produced with dynamic multileaf collimation
19. Planning, delivery, and quality assurance of intensity-modulated radiotherapy using dynamic multileaf collimator: A strategy for large-scale implementation for the treatment of carcinoma of the prostate
20. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer
21. Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy
22. Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: Reducing the potential morbidity of therapy
23. Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: Analysis of RTOG studies 7506 and 7706
24. Consensus statement: Guidelines for PSA following radiation therapy
25. Evaluation of radiation effect, tumor differentiation and prostate specific antigen staining in sequential prostate biopsies after external beam radiotherapy for patients with prostate carcinoma
26. Histopathologic effects of three dimensional conformal external beam radiation therapy on benign and malignant prostate tissues
27. Nonparametric estimation from incomplete observations
28. Evaluation of survival data and two new rank order statistics arising in its consideration
29. Regression models and life tables
30. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: Therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores
31. Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of >4-20 ng/ml
32. Dose selection for prostate cancer patients based on dose comparison and dose response studies
33. Preliminary results of a randomized radiotherapy dose escalation study comparing 70 Gy to 78 Gy for prostate cancer
34. Importance of high radiation doses (72 Gy or greater) in the treatment of stage T1-T3 adenocarcinoma of the prostate
35. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin
36. Phase III trial of androgen suppression using goserelin in unfavorable prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group Protocol 85-31
37. Late rectal toxicity after conformal radiotherapy of prostate cancer (I): Multivariate analysis and dose-response
38. Complications from radiotherapy dose escalation in prostate cancer: Preliminary results of a randomized trial